新诊断早期与晚期子宫内膜癌的遗传与分子亚型异质性
该研究对175例新诊断子宫内膜癌(135例FIGO I/II期,40例III/IV期)进行410-468个癌症相关基因测序,并纳入99例晚期病例数据比较。所有肿瘤均可分入p53野生型(43%)、MMR缺陷型(28%)、p53异常型(22%)和POLE型(7%)。晚期子宫内膜样癌基因组改变比例和ARID1B突变显著高于早期,晚期浆液性癌ERBB2扩增和PIK3CA突变更常见。
要点
- 所有组织学类型均可分入四种分子亚型,分布因组织学类型而异。
- 63%的肿瘤存在潜在治疗靶点,包括高肿瘤突变负荷、ERBB2扩增和PIK3CA热点突变。
- 晚期子宫内膜样癌基因组改变比例和ARID1B突变显著高于早期。
核心结论
- 子宫内膜癌组织学类型内部和之间存在分子异质性,晚期病例基因组复杂性增加。
- 分子亚型跨组织学类型存在,可能有助于对患者进行预后和治疗分层。
研究设计与样本
- 前瞻性纳入175例新诊断子宫内膜癌(7种组织学类型;135例FIGO I/II期,40例III/IV期),对410-468个癌症相关基因进行大规模平行测序。
- 检索99例额外晚期子宫内膜癌的已报告测序数据用于比较。
主要发现
- 175例中p53野生型75例(43%)、MMR缺陷型49例(28%)、p53异常型39例(22%)、POLE型12例(7%)。
- 63%(110例)的肿瘤存在潜在治疗靶点,包括高肿瘤突变负荷、ERBB2扩增和PIK3CA热点突变。
- 晚期子宫内膜样癌基因组改变比例中位数12% vs 早期0.1%(p < 0.001),ARID1B突变11% vs 0%(p = 0.01)。
- 晚期浆液性癌ERBB2扩增18% vs 8%(p > 0.05),PIK3CA突变46% vs 27%(p > 0.05)。
- 全基因组倍增见于晚期癌肉瘤和透明细胞癌,早期未见。
临床怎么用
- 可依据分子亚型对子宫内膜癌患者进行预后评估和治疗分层。
- 应关注高肿瘤突变负荷、ERBB2扩增和PIK3CA热点突变等潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize and compare the molecular subtypes and profiles of prospectively-accrued newly-diagnosed early- and advanced-stage endometrial cancers (ECs). METHODS: EC patients consented to an IRB-approved protocol of massively parallel sequencing of 410-468 cancer-related genes; 175 ECs of 7 histologic types (n = 135 FIGO stages I/II, n = 40 FIGO stages III/IV) were included. Previously reported sequencing data from 99 additional advanced-stage ECs were retrieved for comparisons. RESULTS: Irrespective of histologic type, all 175 ECs could be stratified into the molecular subtypes, with 75 (43%) being of p53 wild-type, 49 (28%) MMR-deficient, 39 (22%) p53 abnormal and 12 (7%) of POLE molecular subtypes. Subtype distribution, mutational and copy number profiles varied according to histologic type. In endometrioid ECs, genetic alterations varied according to histologic grade. Potential therapeutic targets, including high tumor mutational burden, ERBB2 amplification and PIK3CA hotspot mutations, were found across histologic types in 63% (n = 110) of all ECs. Compared to their early-stage counterparts, advanced-stage endometrioid ECs had a significantly higher fraction of genome altered (median 0.1% vs 12%, p < 0.001) and ARID1B mutations (0% vs 11%, p = 0.01), and advanced-stage serous ECs harbored more frequent ERBB2 amplification (18% vs 8%, p > 0.05) and PIK3CA mutations (46% vs 27%, p > 0.05). Whole-genome doubling was found in advanced- but not early-stage carcinosarcomas and clear cell carcinomas. CONCLUSIONS: Our findings demonstrate the molecular heterogeneity within and across histologic types of EC and the increased genomic complexity of advanced-stage ECs. Molecular subtypes are present across EC histologic types and may help stratify EC patients for prognostic and therapeutic purposes.
引用
- Da Cruz Paula A, DeLair DF, Ferrando L, et al. Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecol Oncol. 2021. PMID: 33622519. doi:10.1016/j.ygyno.2021.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。